^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    DRUG CLASS:

    IL-2 stimulant

    Related drugs:
    Apply
    Phase II Trial of Combination Anti-PD-1 and Aldesleukin for Metastatic Melanoma and Renal Cell Carcinoma (NCT05155033)
    Phase 2
    National Cancer Institute (NCI)
    Recruiting
    Last update posted :
    02/21/2025
    Initiation :
    08/18/2022
    Primary completion :
    09/01/2026
    Completion :
    09/01/2027
    PD-L1
    |
    Keytruda (pembrolizumab) • Proleukin (aldesleukin)
    Lymphodepletion Plus Adoptive Cell Transfer With High Dose IL-2 in Patients With Metastatic Melanoma (NCT01005745)
    Phase N/A
    H. Lee Moffitt Cancer Center and Research Insti...
    Active, not recruiting
    Last update posted :
    02/19/2025
    Initiation :
    10/20/2009
    Primary completion :
    01/31/2014
    Completion :
    03/01/2025
    IFNG
    |
    cyclophosphamide • fludarabine IV • Proleukin (aldesleukin)
    Efficacy of Interleukin-2 in Triple Negative Breast Cancer (NCT05821686)
    Phase 1/2
    Nova Scotia Health Authority
    Not yet recruiting
    Last update posted :
    02/12/2025
    Initiation :
    01/02/2026
    Primary completion :
    04/01/2028
    Completion :
    04/01/2028
    PD-L1
    |
    PD-L1 expression
    |
    Proleukin (aldesleukin)
    Three Schedules of CUE-101 Administered Before Surgery or Definitive Chemoradiation Therapy in HLA-A*0201 Positive Patients With Locally Advanced, HPV16-Positive Oropharyngeal Squamous-Cell Carcinoma (NCT04852328)
    Phase 2
    Washington University School of Medicine
    Recruiting
    Last update posted :
    02/06/2025
    Initiation :
    12/06/2021
    Primary completion :
    10/31/2027
    Completion :
    10/31/2027
    CDKN2A • CD8 • IFNG
    |
    CDKN2A expression
    |
    CUE-101
    Isotretinoin With or Without Dinutuximab, Aldesleukin, and Sargramostim Following Stem Cell Transplant in Treating Patients With Neuroblastoma (NCT00026312)
    Phase 3
    National Cancer Institute (NCI)
    Active, not recruiting
    Last update posted :
    02/04/2025
    Initiation :
    10/18/2001
    Primary completion :
    01/12/2012
    Completion :
    03/07/2025
    MYCN • NCR3LG1
    |
    Proleukin (aldesleukin) • Qarziba (dinutuximab beta) • Unituxin (dinutuximab) • Leukine (sargramostim)
    Entinostat in Combination With Aldesleukin in Treating Patients With Metastatic Kidney Cancer (NCT01038778)
    Phase 1/2
    National Cancer Institute (NCI)
    Active, not recruiting
    Last update posted :
    02/03/2025
    Initiation :
    10/29/2009
    Primary completion :
    05/22/2019
    Completion :
    07/30/2025
    mTOR
    |
    Jingzhuda (entinostat) • Proleukin (aldesleukin)
    Dose Escalation and Expansion Study of WTX-124 As Monotherapy and in Combination with Pembrolizumab (pembro) in Patients with Selected Advanced or Metastatic Solid Tumors (KEYNOTE-D17) (NCT05479812)
    Phase 1
    Werewolf Therapeutics, Inc.
    Recruiting
    Last update posted :
    12/27/2024
    Initiation :
    05/20/2022
    Primary completion :
    07/01/2025
    Completion :
    07/31/2025
    PD-L1
    |
    Keytruda (pembrolizumab) • WTX-124
    IT-hu14.18-IL2 With Radiation, Nivolumab and Ipilimumab for Melanoma (A534260) (NCT03958383)
    Phase 1/2
    University of Wisconsin, Madison
    Suspended
    Last update posted :
    09/19/2024
    Initiation :
    01/30/2020
    Primary completion :
    08/15/2025
    Completion :
    08/15/2026
    IL2
    |
    PD-L1 expression
    |
    Opdivo (nivolumab) • Yervoy (ipilimumab) • lorukafusp alfa (APN301)
    A Phase 1 Study in Patients With HPV16+ Recurrent/ Metastatic Head and Neck Squamous Cell Carcinoma (KEYNOTE-A78) (NCT03978689)
    Phase 1
    Cue Biopharma
    Active, not recruiting
    Last update posted :
    08/01/2024
    Initiation :
    07/30/2019
    Primary completion :
    11/01/2024
    Completion :
    05/01/2025
    CDKN2A • CTLA4
    |
    PD-L1 expression • CDKN2A expression
    |
    Keytruda (pembrolizumab) • CUE-101
    Administering Peripheral Blood Lymphocytes Transduced With a Murine T-Cell Receptor Recognizing the G12D Variant of Mutated RAS in HLA-A*11:01 Patients (19-C-0017) (NCT03745326)
    Phase 1/2
    National Cancer Institute (NCI)
    Recruiting
    Last update posted :
    06/05/2024
    Initiation :
    05/16/2019
    Primary completion :
    12/01/2027
    Completion :
    12/01/2028
    EGFR • PD-L1 • KRAS • ALK • NRAS • HRAS
    |
    PD-L1 expression • KRAS mutation • NRAS mutation • KRAS G12D • EGFR expression • HRAS mutation • KRAS G12 • NRAS G12D • NRAS G12 • HLA-A*11
    |
    cyclophosphamide • fludarabine IV • Proleukin (aldesleukin) • anti-KRAS G12D mTCR PBL • cyclophosphamide intravenous
    Administering Peripheral Blood Lymphocytes Transduced With a Murine T-Cell Receptor Recognizing the G12V Variant of Mutated RAS in HLA-A*11:01 Patients (NCT03190941)
    Phase 1/2
    National Cancer Institute (NCI)
    Recruiting
    Last update posted :
    06/05/2024
    Initiation :
    09/21/2017
    Primary completion :
    06/29/2027
    Completion :
    06/29/2028
    KRAS • ALK • NRAS • HRAS
    |
    KRAS mutation • NRAS mutation • KRAS G12V • HRAS mutation • KRAS G12 • NRAS G12 • HLA-A*11 • NRAS G12V
    |
    cyclophosphamide • fludarabine IV • Proleukin (aldesleukin) • cyclophosphamide intravenous
    The Efficacy and Safety of IBI363 in Solid Tumors (Promise) (NCT06081907)
    Phase 1/2
    Hunan Province Tumor Hospital
    Recruiting
    Last update posted :
    05/30/2024
    Initiation :
    12/25/2023
    Primary completion :
    12/01/2026
    Completion :
    09/01/2028
    EGFR • HER-2 • PD-L1 • BRAF • ALK • RET • CD73 • NTRK
    |
    BRAF V600E • EGFR mutation • BRAF V600 • RET fusion • ALK fusion • ALK mutation
    |
    erlotinib • Lenvima (lenvatinib)
    Phase I/II Study of Autologous T Cells to Express T-Cell Receptors (TCRs) in Subjects With Solid Tumors (NCT05194735)
    Phase 1/2
    Alaunos Therapeutics
    Active, not recruiting
    Last update posted :
    05/29/2024
    Initiation :
    04/04/2022
    Primary completion :
    11/30/2024
    Completion :
    11/30/2024
    IFNG • IL6 • TNFA • IL2
    |
    MSI-H/dMMR
    |
    Proleukin (aldesleukin)
    CD8+ Antigen-Specific T Cells, Cyclophosphamide, Aldesleukin, and Ipilimumab in Treating Patients With Metastatic Melanoma (NCT02027935)
    Phase 2
    M.D. Anderson Cancer Center
    Completed
    Last update posted :
    05/10/2024
    Initiation :
    01/22/2015
    Primary completion :
    04/12/2024
    Completion :
    04/12/2024
    BRAF • IL2 • MLANA
    |
    BRAF mutation • BRAF V600
    |
    Yervoy (ipilimumab) • cyclophosphamide • Proleukin (aldesleukin) • cyclophosphamide intravenous
    T-Cell Infusion, Aldesleukin, and Utomilumab in Treating Patients With Recurrent Ovarian Cancer (NCT03318900)
    Phase 1/2
    M.D. Anderson Cancer Center
    Completed
    Last update posted :
    05/08/2024
    Initiation :
    07/16/2018
    Primary completion :
    12/20/2023
    Completion :
    12/20/2023
    HLA-A • PRAME • COL6A3
    |
    PRAME expression
    |
    cyclophosphamide • Proleukin (aldesleukin) • utomilumab (PF-05082566) • cyclophosphamide intravenous
    Genetically Modified T-Cells Followed by Aldesleukin in Treating Patients With Stage III-IV Melanoma (NCT01955460)
    Phase 1
    M.D. Anderson Cancer Center
    Active, not recruiting
    Last update posted :
    04/19/2024
    Initiation :
    10/15/2014
    Primary completion :
    06/01/2024
    Completion :
    06/01/2025
    NGFR • TGFA
    |
    TILs
    |
    cyclophosphamide • fludarabine IV • Proleukin (aldesleukin) • cyclophosphamide intravenous
    A Study Evaluating Safety and Therapeutic Activity of THOR-707 in Adult Subjects With Advanced or Metastatic Solid Tumors (THOR-707-101) (HAMMER) (NCT04009681)
    Phase 1/2
    Synthorx, Inc, a Sanofi company
    Recruiting
    Last update posted :
    04/05/2024
    Initiation :
    06/20/2019
    Primary completion :
    06/01/2026
    Completion :
    06/01/2026
    KRAS
    |
    KRAS mutation
    |
    Keytruda (pembrolizumab) • Erbitux (cetuximab) • pegenzileukin (SAR444245)
    Autologous CD19 CAR-T Cell Therapy (SYNCAR-001) + Orthogonal IL-2 (STK-009) in Subjects With CD19+ Hematologic Malignancies (NCT05665062)
    Phase 1
    Synthekine
    Recruiting
    Last update posted :
    03/21/2024
    Initiation :
    06/24/2022
    Primary completion :
    06/24/2026
    Completion :
    11/01/2026
    CD19
    |
    CD19 expression
    |
    cyclophosphamide • fludarabine IV • STK-009/SYNCAR-001
    TNFalpha and Interleukin 2 Coding Oncolytic Adenovirus TILT-123 During TIL Treatment of Advanced Melanoma (TUNINTIL) (NCT04217473)
    Phase 1
    TILT Biotherapeutics Ltd.
    Active, not recruiting
    Last update posted :
    03/11/2024
    Initiation :
    02/26/2020
    Primary completion :
    12/12/2023
    Completion :
    12/01/2024
    BRAF • IL2
    |
    TILs
    |
    igrelimogene litadenorepvec (TILT-123)
    A Study to Compare Bempegaldesleukin (BEMPEG: NKTR-214) Combined With Nivolumab and Tyrosine Kinase Inhibitor (TKI) to Nivolumab and TKI Alone in Participants With Previously Untreated Kidney Cancer That is Advanced or Has Spread (PIVOT IO 011) (NCT04540705)
    Phase 1
    Bristol-Myers Squibb
    Completed
    Last update posted :
    02/28/2024
    Initiation :
    09/11/2020
    Primary completion :
    01/18/2024
    Completion :
    01/18/2024
    PD-L1
    |
    Opdivo (nivolumab) • Cabometyx (cabozantinib tablet) • Inlyta (axitinib) • bempegaldesleukin (NKTR-214)
    Lymphodepletion Plus Adoptive Cell Transfer With or Without Dendritic Cell Immunization in Patients With Metastatic Melanoma (NCT00338377)
    Phase 2
    M.D. Anderson Cancer Center
    Active, not recruiting
    Last update posted :
    02/07/2024
    Initiation :
    02/01/2006
    Primary completion :
    02/28/2030
    Completion :
    02/28/2030
    IL2
    |
    cyclophosphamide • fludarabine IV • mesna • Proleukin (aldesleukin) • cyclophosphamide intravenous
    Study of High Dose Interleukin-2 (IL-2) and Stereotactic Body Radiation (SBRT) in Patients With Metastatic Renal Cancer (NCT02306954)
    Phase 2
    Providence Health & Services
    Active, not recruiting
    Last update posted :
    01/25/2024
    Initiation :
    12/01/2014
    Primary completion :
    12/01/2024
    Completion :
    12/01/2026
    IL2
    |
    Proleukin (aldesleukin)
    Autologous CD8+ SLC45A2-Specific T Lymphocytes With Cyclophosphamide, Aldesleukin, and Ipilimumab in Treating Patients With Metastatic Uveal Melanoma (NCT03068624)
    Phase 1
    M.D. Anderson Cancer Center
    Active, not recruiting
    Last update posted :
    01/25/2024
    Initiation :
    09/08/2017
    Primary completion :
    12/31/2022
    Completion :
    07/31/2025
    IL2
    |
    Yervoy (ipilimumab) • cyclophosphamide • Proleukin (aldesleukin) • cyclophosphamide intravenous
    CD19-specific T Cell Infusion in Patients With B-Lineage Lymphoid Malignancies (NCT00968760)
    Phase 1
    M.D. Anderson Cancer Center
    Completed
    Last update posted :
    12/19/2023
    Initiation :
    06/20/2011
    Primary completion :
    04/23/2020
    Completion :
    04/23/2020
    IL2
    |
    cytarabine • etoposide IV • carmustine • melphalan • Proleukin (aldesleukin) • Depocyte (liposomal cytarabine)
    Gene and Vaccine Therapy in Treating Patients With Advanced Malignancies (NCT01697527)
    Phase 2
    Jonsson Comprehensive Cancer Center
    Active, not recruiting
    Last update posted :
    12/11/2023
    Initiation :
    11/02/2012
    Primary completion :
    11/02/2024
    Completion :
    11/02/2025
    CTAG1B
    |
    cyclophosphamide • fludarabine IV • Proleukin (aldesleukin) • cyclophosphamide intravenous
    T-regulatory Cell Depletion With E7777 Combined With Pembrolizumab in Recurrent or Metastatic Solid Tumors (NCT05200559)
    Phase 1/2
    Haider Mahdi
    Recruiting
    Last update posted :
    11/09/2023
    Initiation :
    09/30/2022
    Primary completion :
    12/01/2025
    Completion :
    12/01/2027
    MSI • CD4 • IL2
    |
    MSI-H/dMMR
    |
    Keytruda (pembrolizumab) • Lymphir (denileukin diftitox-cxdl)
    Donor Natural Killer Cells and Donor Stem Cell Transplant in Treating Patients With High Risk Myeloid Malignancies (NCT01823198)
    Phase 1/2
    M.D. Anderson Cancer Center
    Completed
    Last update posted :
    11/07/2023
    Initiation :
    06/11/2013
    Primary completion :
    05/10/2022
    Completion :
    05/10/2022
    FLT3 • DNMT3A • TET2
    |
    FLT3 mutation • KIT mutation • DNMT3A mutation • TET2 mutation
    |
    fludarabine IV • Proleukin (aldesleukin) • busulfan
    A Study of NKTR-214 Combined With Nivolumab vs Nivolumab Alone in Participants With Previously Untreated Inoperable or Metastatic Melanoma (PIVOT IO 001) (NCT03635983)
    Phase 3
    Bristol-Myers Squibb
    Completed
    Last update posted :
    10/18/2023
    Initiation :
    09/21/2018
    Primary completion :
    11/19/2021
    Completion :
    09/06/2023
    PD-L1
    |
    PD-L1 expression
    |
    Opdivo (nivolumab) • bempegaldesleukin (NKTR-214)
    Modified T Cells, Chemotherapy, and Aldesleukin With or Without LV305 and CMB305 in Treating Participants With Advanced or Recurrent Sarcoma (NCI-2018-00926) (NCT03450122)
    Phase 1
    M.D. Anderson Cancer Center
    Completed
    Last update posted :
    10/16/2023
    Initiation :
    09/13/2018
    Primary completion :
    12/06/2022
    Completion :
    12/06/2022
    HLA-A • CTAG1B
    |
    cyclophosphamide • Proleukin (aldesleukin) • CMB305 • ID-LV305 • cyclophosphamide intravenous
    E7 T-cell Receptor (TCR) -T Cell Induction Therapy for Locoregionally Advanced HPV-associated Cancers (NCT05639972)
    Phase 1/2
    Christian Hinrichs
    Not yet recruiting
    Last update posted :
    10/11/2023
    Initiation :
    06/12/2024
    Primary completion :
    10/01/2026
    Completion :
    10/01/2026
    HLA-A
    |
    HLA-A*02
    |
    cyclophosphamide • Proleukin (aldesleukin) • E7 TCR cells • E7 TCR-T
    A Phase 1 in Patients With HLA-A*0201+ and WT1+ Recurrent/Metastatic Cancers (NCT05360680)
    Phase 1
    Cue Biopharma
    Recruiting
    Last update posted :
    09/27/2023
    Initiation :
    06/14/2022
    Primary completion :
    12/01/2024
    Completion :
    12/01/2026
    WT1 • CTLA4
    |
    WT1 expression • WT1 positive
    |
    CUE-102
    Adoptive Cell Therapy Using Cancer Specific CD8+ Tumor Infiltrating Lymphocytes in Adult Patients With Solid Tumors (ACT) (NCT05902520)
    Phase 1
    AgonOx, Inc.
    Recruiting
    Last update posted :
    07/20/2023
    Initiation :
    06/19/2023
    Primary completion :
    05/19/2025
    Completion :
    05/19/2026
    BRAF • CD8
    |
    AGX-148